Ken Griffin Global Blood Therapeutics, Inc. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$32.4 - $68.18 $42.1 Million - $88.6 Million	-1,300,157 Reduced 96.2%	51,397 $3.5 Million
Q2 2022 Aug 15, 2022	SELL	$22.3 - $37.39 $13.7 Million - $23 Million	-614,378 Reduced 31.25%	1,351,554 $43.2 Million
Q1 2022 May 16, 2022	BUY	$25.68 - $35.59 $7.19 Million - $9.97 Million	280,076 Added 16.61%	1,965,932 $68.1 Million
Q4 2021 Feb 14, 2022	BUY	$24.9 - $40.26 $41.1 Million - $66.5 Million	1,650,927 Added 4726.52%	1,685,856 $49.3 Million
Q3 2021 Nov 15, 2021	SELL	$25.48 - $37.34 $27.1 Million - $39.7 Million	-1,062,624 Reduced 96.82%	34,929 $890,000
Q1 2021 May 17, 2021	BUY	$38.94 - $50.85 $28 Million - $36.6 Million	720,308 Added 190.94%	1,097,553 $44.7 Million
Q4 2020 Feb 16, 2021	SELL	$37.65 - $63.77 $11.3 Million - $19.1 Million	-298,927 Reduced 44.21%	377,245 $16.3 Million
Q3 2020 Nov 16, 2020	BUY	$52.76 - $74.49 $20.3 Million - $28.7 Million	385,407 Added 132.55%	676,172 $37.3 Million
Q2 2020 Aug 14, 2020	BUY	$48.73 - $81.82 $4.98 Million - $8.36 Million	102,171 Added 54.18%	290,765 $18.4 Million
Q1 2020 May 15, 2020	BUY	$41.72 - $87.2 $51,899 - $108,476	1,244 Added 0.66%	188,594 $9.64 Million
Q4 2019 Feb 14, 2020	BUY	$45.7 - $81.86 $7.97 Million - $14.3 Million	174,441 Added 1351.31%	187,350 $14.9 Million
Q3 2019 Nov 14, 2019	SELL	$45.35 - $57.91 $9.74 Million - $12.4 Million	-214,698 Reduced 94.33%	12,909 $626,000
Q2 2019 Aug 14, 2019	BUY	$52.6 - $63.29 $1.55 Million - $1.86 Million	29,402 Added 14.83%	227,607 $12 Million
Q1 2019 May 15, 2019	BUY	$39.99 - $53.48 $6.66 Million - $8.91 Million	166,583 Added 526.79%	198,205 $0
Q4 2018 Feb 14, 2019	SELL	$31.54 - $46.67 $1.22 Million - $1.81 Million	-38,729 Reduced 55.05%	31,622 $1.3 Million
Q3 2018 Nov 13, 2018	BUY	$38.0 - $51.1 $1.51 Million - $2.02 Million	39,619 Added 128.92%	70,351 $0
Q2 2018 Aug 10, 2018	SELL	$38.7 - $50.15 $742,188 - $961,776	-19,178 Reduced 38.43%	30,732 $0
Q1 2018 May 11, 2018	SELL	$39.6 - $65.9 $26.4 Million - $43.9 Million	-666,701 Reduced 93.04%	49,910 $2.41 Million
Q4 2017 Feb 09, 2018	BUY	$29.7 - $45.7 $13.4 Million - $20.6 Million	449,828 Added 168.61%	716,611 $28.2 Million
Q3 2017 Nov 09, 2017	BUY	$25.1 - $31.05 $6.7 Million - $8.28 Million	266,783	266,783 $8.28 Million

Others Institutions Holding GBT

# of Institutions

Shares Held

288K

Call Options Held

Put Options Held

View Full List

About Global Blood Therapeutics, Inc.

Ticker GBT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,476,200
Market Cap $4.62B
Description
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses...

More about GBT

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account